Valion Bio, Inc.
9.90%
1,742,699
1787740
Aug 11, 2026
Aug 14, 2026, 07:15 PM
Reporting Persons (4)
This is a joint filing. The reported shares may overlap between reporting persons and should not be summed.
| Name | Type | % of Class | Aggregate | Sole Voting | Shared Voting |
|---|---|---|---|---|---|
| 3i, LP | Partnership | 9.90% | 1,742,699 | 0 | 1,742,699 |
| 3i Management LLC | Other | 9.90% | 1,742,699 | 0 | 1,742,699 |
| Maier J. Tarlow | Individual | 9.90% | 1,742,699 | 0 | 1,742,699 |
| Tumim Stone Capital, LLC | Other | 0.00% | 0 | 0 | 0 |
Disclosure Items (7)
Common Stock
Valion Bio, Inc.
1305 E. Houston Street, San Antonio, TX, 78205
This Item 2(a) is not being amended by this Amendment No. 2.
This Item 2(b) is not being amended by this Amendment No. 2.
This Item 2(c) is not being amended by this Amendment No. 2.
This Item 2(e) is not being amended by this Amendment No. 2.
This Item 2(f) is not being amended by this Amendment No. 2.
This Item 3 is not being amended by this Amendment No. 2.
Item 5(a) of the Original Schedule 13D is hereby amended and restated as follows: See rows (11) and (13) of the cover pages to this statement for the aggregate number of shares of Common Stock and percentages of the shares of Common Stock beneficially owned by each of the Reporting Persons. The shares and percentages are based on 15,776,805 shares of Common Stock outstanding, consisting of (a) 4,151,259 shares of Common Stock as of July 7, 2026 as disclosed in the Proxy Statement, (b) 256,105 shares of Common Stock issued to 3i, LP on July 19, 2026 pursuant to conversions of certain shares of Series B Preferred Stock, (c) 846,666 shares of Common Stock issued to 3i, LP on August 12, 2026 pursuant to conversions of certain shares of Series B Preferred Stock, (d) 9,260,042 shares of Common Stock issued to 3i, LP on August 12, 2026 pursuant to conversions of certain shares of Series C Preferred Stock and (e) 1,262,733 shares of Common Stock issued to 3i, LP on August 13, 2026 pursuant to conversions of certain shares of Series C Preferred Stock.
This Item 5(b) is not being amended by this Amendment No. 2.
This Item 5(c) is hereby amended to add the transactions set forth in Exhibit 5 attached herein.
This Item 5(d) is not being amended by this Amendment No. 2.
This Item 5(e) is not being amended by this Amendment No. 2.
This Item 6 is not being amended by this Amendment No. 2.
Item 7 of the Original Schedule 13D is hereby amended to add the following exhibit: Exhibit 5: Additional Transactions